SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:9609148a-0516-47d7-897a-543050cdfdfb"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:9609148a-0516-47d7-897a-543050cdfdfb" > A biological marker...

A biological marker, strongly associated with early oral contraceptive use, for the selection of a high risk group for premenopausal breast cancer

Olsson, H., (författare)
Lunds universitet, Lund University, Medicinska fakulteten, Faculty of Medicine, Institutionen för kliniska vetenskaper, Lund, Department of Clinical Sciences, Lund, Tumörmikromiljö, Tumor microenvironment, Sektion I, Section I, Skåne University Hospital
Borg, Å, (författare)
Lunds universitet, Lund University, Medicinska fakulteten, Faculty of Medicine, Institutionen för kliniska vetenskaper, Lund, Department of Clinical Sciences, Lund, Bröstca-genetik, Breastca-genetics, Sektion I, Section I, Skåne University Hospital
Ewers, S. B. (författare)
visa fler...
Fernö, M., (författare)
Lunds universitet, Lund University, Medicinska fakulteten, Faculty of Medicine, Institutionen för kliniska vetenskaper, Lund, Department of Clinical Sciences, Lund, Bröstca-genetik, Breastca-genetics, Sektion I, Section I, Skåne University Hospital
Möller, T., (författare)
Southern Swedish General Tumour Registry
Ranstam, J. (författare)
visa färre...
1986
Engelska.
Ingår i: Medical Oncology and Tumor Pharmacotherapy. - Humana Press. - 0736-0118. ; 3:2, s. 77-81
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • In a population-based group of women, consecutively diagnosed, with premenopausal breast cancer there was a significant correlation between tumour size and plasma prolactin (r=0.30;P<0.004). The concentration of estrogen receptor was negatively correlated to tumour size (r=-0.17;P<0.09). There were no substantial correlations between tumour size and progesterone receptor, plasma progesterone or estradiol. Adjustments for menstrual cycle day and age did not alter the above findings. The ratio of plasma prolactin and estrogen receptor was significantly greater (P<0.037) for the group of the patients that had started using oral contraceptives before the age of 20 as compared with the other patients. Consequently, the tumour size was significantly greater in the group of early users (P<0.003). The findings indicate that breast tumours developing in previous early users of oral contraceptives have a low estrogen receptor concentration, while these patients have plasma prolactin. The tumour size is greater in early users indicating a poorer prognosis than other women with breast cancer. As early use of oral contraceptives increases, breast cancer risk and a high ratio of plasma prolactin and estrogen receptor concentration of the primary tumour characterize early oral contraceptive users the ratio may be a valuable marker for the breast cancer risk.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Estrogen receptor
Marker
Oral contraceptive use
Plasma prolactin
Premenopausal breast cancer
Progesterone receptor

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)
art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...
Olsson, H.
Borg, Å
Ewers, S. B.
Fernö, M.
Möller, T.
Ranstam, J.
Om ämnet
MEDICIN OCH HÄLSOVETENSKAP
MEDICIN OCH HÄLS ...
och Klinisk medicin
och Cancer och onkol ...
Artiklar i publikationen
Medical Oncology ...
Av lärosätet
Lunds universitet

Sök utanför SwePub

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy